Research graph
References from Case Report: Reopening the anabolic window — romosozumab added to ongoing denosumab for severe osteoporosis in two kidney transplant recipients. Local targets link to admitted publications; unresolved targets remain external evidence.
Bone mineral disease after kidney transplantation
10.1007/s00223-021-00837-0 · 2021 · External reference
Bone disease after kidney transplantation
10.2215/cjn.11371015 · 2016 · External reference
Risk of fractures after renal transplantation in the United States
10.1097/tp.0b013e3181a6bbda · 2009 · External reference
Natural history of bone disease following kidney transplantation
10.1681/asn.2021081081 · 2022 · External reference
Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients
10.1016/j.kint.2018.12.024 · 2019 · External reference
Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what’s changed and why it matters
10.1016/j.kint.2017.04.006 · 2017 · External reference
Calcium and calcitriol prophylaxis attenuates posttransplant bone loss
10.1097/01.tp.0000137937.44703.42 · 2004 · External reference
Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study
10.1097/01.asn.0000016082.70875.36 · 2002 · External reference
Bone and mineral disease in kidney transplant recipients
10.2215/cjn.03410321 · 2022 · External reference
Chronic kidney disease–mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference
10.1016/j.kint.2024.11.013 · 2025 · External reference
Clinical efficacy and safety of pamidronate therapy on bone mass density in early post-renal transplant period: a meta-analysis of randomized controlled trials
10.1371/journal.pone.0108106 · 2014 · External reference
Alendronate prevents further bone loss in renal transplant recipients
10.1359/jbmr.2001.16.11.2111 · 2001 · External reference
Bisphosphonate use after kidney transplantation is associated with lower fracture risk
10.2215/cjn.0000000591 · 2025 · External reference
Bisphosphonates in kidney disease—safety first
10.1002/jbmr.4283 · 2020 · External reference
Denosumab-induced hypocalcemia and hyperparathyroidism in de novo kidney transplant recipients
10.1159/000518363 · 2021 · External reference
Effect of twice-yearly denosumab on prevention of bone mineral density loss in de novo kidney transplant recipients: a randomized controlled trial
10.1111/ajt.13692 · 2016 · External reference
Modeling-based bone formation after 2 months of romosozumab treatment: results from the FRAME clinical trial
10.1002/jbmr.4457 · 2020 · External reference
Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis
10.1177/1759720x16670154 · 2016 · External reference
Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational study
10.1093/jbmrpl/ziae016 · 2024 · External reference
Unsolved issues in managing CKD-associated osteoporosis: myths, facts, and clinical grey zones
10.34067/kid.0000001303 · 2026 · External reference
Sequential and combination therapy with romosozumab
10.1007/s00774-025-01590-2 · 2025 · External reference
Romosozumab or alendronate for fracture prevention in women with osteoporosis
10.1056/nejmoa1708322 · 2017 · External reference
Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease
10.1002/jbmr.4563 · 2020 · External reference
Romosozumab and denosumab combination therapy after denosumab in postmenopausal osteoporosis
10.1002/art.70002 · 2026 · External reference
Preliminary analysis of combined romosozumab and denosumab versus teriparatide and denosumab on bone mineral density
10.1016/j.afos.2025.11.002 · 2025 · External reference
Efficacy comparison of 6-month romosozumab plus denosumab versus 12-month romosozumab in Koreans
10.1093/ejendo/lvaf211 · 2025 · External reference
Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-naïve primary osteoporosis: a retrospective cohort study
10.1016/j.bone.2025.117627 · 2025 · External reference
3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial
10.1016/s2213-8587(25)00319-5 · 2026 · External reference
Efficacy of romosozumab followed by denosumab in glucocorticoid users; a randomized clinical trial
10.1007/s00198-026-08103-5 · 2026 · External reference
Impact of romosozumab treatment for 24 months after switching from denosumab: three case reports
10.1093/jbmrpl/ziaf070 · 2025 · External reference
One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study
10.1002/jbmr.3622 · 2019 · External reference
Romosozumab for managing severe osteoporosis in patients undergoing kidney transplantation: a retrospective case series
10.1093/jbmrpl/ziaf049 · 2025 · External reference
